Poly(lactic acid-glycolic acid) nanoparticles markedly improve immunological protection provided by peptide P10 against murine paracoccidioidomycosis
Contribuinte(s) |
UNIVERSIDADE DE SÃO PAULO |
---|---|
Data(s) |
20/10/2012
20/10/2012
2010
|
Resumo |
Background and purpose: The present study reports on the preparation and testing of a sustained delivery system for the immunomodulatory peptide P10 aimed at reducing the in vivo degradation of the peptide and the amount required to elicit a protective immune response against paracoccidioidomycosis. Experimental approach: BALB/c mice were infected with the yeast Paracoccidioides brasiliensis to mimic the chronic form of paracoccidioidomycosis. The animals were treated daily with sulfamethoxazole/trimethoprim alone or combined with peptide P10, either emulsified in Freund`s adjuvant or entrapped in poly(lactic acid-glycolic acid) (PLGA) nanoparticles at different concentrations (1 mu g, 5 mu g, 10 mu g, 20 mu g or 40 mu g center dot 50 mu L-1). Therapeutic efficacy was assessed as fungal burden in tissues and the immune response by quantitative determination of cytokines. Key results: Animals given combined chemotherapy and P10 nanotherapy presented a marked reduction of fungal load in the lungs, compared with the non-treated animals. After 30 days of treatment, P10 entrapped within PLGA (1 mu g center dot 50 mu L-1) was more effective than `free` P10 emulsified in Freund`s adjuvant (20 mu g center dot 50 mu L-1), as an adjuvant to chemotherapy. After treatment for 90 days, the higher doses of P10 entrapped within PLGA (5 or 10 mu g center dot 50 mu L-1) were most effective. Treatment with P10 emulsified in Freund`s adjuvant (20 mu g center dot 50 mu L-1) or P10 entrapped within PLGA (1 mu g center dot 50 mu L-1) were accompanied by high levels of interferon-gamma in lung. Conclusions and implications: Combination of sulfamethoxazole/trimethoprim with the P10 peptide entrapped within PLGA demonstrated increased therapeutic efficacy against paracoccidioidomycosis. P10 incorporation into PLGA nanoparticles dramatically reduced the peptide amount necessary to elicit a protective effect. Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) |
Identificador |
BRITISH JOURNAL OF PHARMACOLOGY, v.159, n.5, p.1126-1132, 2010 0007-1188 http://producao.usp.br/handle/BDPI/28426 10.1111/j.1476-5381.2009.00617.x |
Idioma(s) |
eng |
Publicador |
WILEY-BLACKWELL PUBLISHING, INC |
Relação |
British Journal of Pharmacology |
Direitos |
restrictedAccess Copyright WILEY-BLACKWELL PUBLISHING, INC |
Palavras-Chave | #immunomodulatory peptide #antifungal therapy #biodegradable polymers #drug delivery #nanobiotechnology #T-CELL EPITOPE #IN-VITRO #BRASILIENSIS #PLGA #ANTIGEN #MICE #MICROPARTICLES #MICROSPHERES #CHEMOTHERAPY #INFECTION #Pharmacology & Pharmacy |
Tipo |
article original article publishedVersion |